Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Last Hour:
Last 24 Hours:

TapImmune eyes phase II trial for vaccine early next year

Tuesday, November 1, 2016 7:41
% of readers think this story is Fact. Add your two cents.

Immunotherapy group TapImmune Inc (OTCMKTS:TPIV) plans to apply for a phase II trial of a new formulation of its HER2neu vaccine for breast cancer early next year, it said today.

The vaccine (TPIV 110) consists of four proprietary class II antigens and one proprietary class I antigen.

In the phase I trial, 90% patients developed a ‘robust- T-cell response to the class II antigens, while the class I antigen may be up to four time as more effective at killing breast cancer cells than those tested previously, research has suggested.

A combination of the antigens may be the best combination for a therapeutic response, added TapImmune.

An application to the US Food and Drug Admission for a clinical trial of the vaccine to include the new type 1 antigen peptide is expected around the end of the year.

“HER2neu is a well-known and important target in breast cancer treatments,” said Dr. John Bonfiglio, TapImmune’s chief executive.

“Our strategy is to highly leverage our HER2neu platform technology in treating this disease.”

Story by ProactiveInvestors


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global

Top Alternative



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.